A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia - PubMed
Introduction Oral dutasteride has demonstrated superiority over finasteride in treating androgenetic alopecia (AGA). We have developed a novel topical dutasteride formulation, which has shown promising efficacy, safety, and tolerability in preclinical studies. The present study objective is to...
pubmed.ncbi.nlm.nih.gov